Brussels Interuniversity Genomics High Throughput core (BRIGHTcore) of Vrije Universiteit Brussel (VUB)
Université Libre de Bruxelles (ULB) & Centre for Medical Genetics, Reproduction and Genetics, Reproduction & Genetics and Regenerative Medicine, Vrije Universiteit Brussel (VUB), UZ Brussel, Brussels, Belgium
Ir A. Hébrant PhD, G. Froyen PhD, B. Maes MD, PhD, R. Salgado MD, PhD, M. Le Mercier PhD, N. D’Haene MD, PhD, S. De Keersmaecker PhD, K. Claes PhD, J. Van der Meulen MD, P. Aftimos MD, J. Van Houdt PhD, K. Cuppens MD, K. Vanneste PhD, E. Dequeker PhD, S. Van Dooren PhD, J. Van Huysse MD, F. Nollet PhD, S. Van Laere PhD, B. Denys MD, V. Ghislain , C. Van Campenhout PhD, M. Van den Bulcke PhD
Targeted next generation sequencing is a complex procedure including the ‘wet bench’ and ‘dry bench’ parts. Both parts are composed of many steps for which optimal assay conditions and settings must be determined.
The aim of these guidelines is to provide generic, platform independent, recommendations for targeted next generation sequencing tests to detect acquired somatic mutations in DNA, in (haemato)-oncology that are complementary to the ISO 15189 norm (medical laboratories) in order to:
facilitate the implementation of the required quality metrics for the detection of somatic variants by next generation sequencing in oncology and haemato-oncology in the Belgian laboratories,
harmonise test validation and verification,
harmonise clinical interpretation and reporting of variants and,
assure and maintain optimal test performance by establishing procedures and modalities for internal quality control and external quality assessments.
R.B. Shahi MSc, B. Caljon , S. De Brakeleer PhD, L. Decoster MD, PhD, C. Fontaine MD, L. Vanacker MD, M. Vanhoeij , I. Pauwels , M-L. Bonduelle , S. Van Dooren PhD, D. Croes , E. Teugels PhD, J. De Grève MD, PhD